BJU INTERNATIONAL, Vol. 96, Number 2, August 2005, 212-216
European Urology Update Series 2005:4

Nedostatek androgenů a hormonální substituční léčba

ANDREA M. ISIDORI, EMANUELA A. GRECO a ANTONIO AVERSA*
*Cattedra di Andrologia and *Cattedra di Medicina Interna, Dipartimento Fisiopatologia Medica, Università 'La Sapienza'di Roma, Italy*

LITERATURA

1 Vermeulen A, Rubens R, Verdonck L. Testosterone secretion and metabolism in male senescence. *J Clin Endocrinol Metab* 1972; 34: 730–5
2 Gray A, Berlin JA, McKinlay JB, Longcope C. An examination of research design effects on the association of testosterone and male aging: results of a meta-analysis. *J Clin Epidemiol* 1991; 44: 671–84
3 Morley JE, Kaiser FE, Perry HM III *et al.* Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. *Metabolism* 1997; 46: 410–3
4 Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13- year follow-up of former Multiple Risk Factor Intervention Trial participants. *Am J Epidemiol* 1997; 146: 609–17
5 Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. *J Clin Endocrinol Metab* 2001; 86: 724–31
6 Korenman SG, Morley JE, Mooradian AD *et al.* Secondary hypogonadism in older men: its relation to impotence. *J Clin Endocrinol Metab* 1990; 71: 963–9
7 Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. *J Clin Endocrinol Metab* 1991; 73: 1016–25
8 Turner HE, Wass JA. Gonadal function in men with chronic illness. *Clin Endocrinol (Oxf)* 1997; 47: 379–403
9 Morales A, Heaton JP, Carson CC III. Andropause: a misnomer for a true clinical entity. *J Urol* 2000; 163: 705–12
10 Feldman HA, Longcope C, Derby CA *et al.* Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. *J Clin Endocrinol Metab* 2002; 87: 589–98
11 Spark RF, White RA, Connolly PB. Impotence is not always psychogenic. Newer insights into hypothalamicpituitary-gonadal dysfunction. *JAMA* 1980; 243: 750–5
12 Slag MF, Morley JE, Elson MK *et al* Impotence in medical clinic outpatients. *JAMA* 1983; 249: 1736–40
13 Nickel JC, Morales A, Condra M, Fenemore J, Surridge DH. Endocrine dysfunction in impotence: incidence, significance and cost-effective screening. *J Urol* 1984; 132: 40–3
14 Guay AT, Bansal S, Heatley GJ. Effect of raising endogenous testosterone levels in impotent men with secondary hypogonadism: double blind placebocontrolled trial with clomiphene citrate. *J Clin Endocrinol Metab* 1995; 80: 3546–52
15 Govier FE, McClure RD, Kramer-Levien D. Endocrine screening for sexual dysfunction using free testosterone determinations. *J Urol* 1996; 156: 405–8
16 Araujo AB, O'donnell AB, Brambilla DJ *et al.* Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. *J Clin Endocrinol Metab* 2004; 89: 5920–6
17 Gooren L. Androgen deficiency in the aging male: benefits and risks of androgen supplementation. *J Steroid Biochem Mol Biol* 2003; 85: 349–55
18 Tan RS. Andropause. introducing the concept of 'relative hypogonadism' in aging males. *Int J Impot Res* 2002; 14: 319
19 Isidori AM, Giannetta E, Gianfrilli D *et al.* Effects of testosterone on sexual function in men: results of a metaanalysis. *Clin Endocrinol (Oxf)* 2005; in press
20 Isidori AM, Giannetta E, Greco EA *et al.* Effects of testosterone on body composition, bone metabolism and serum lipid profile in aging men: results in a meta-analysis. *Clin Endocrinol (Oxf)* 2005; in press
21 Isidori AM, Lenzi A. Risk factors for androgen decline in older males. lifestyle, metabolic disease and drug. *J Endocrinol*

Invest 2005; 28(suppl 3): 14–23
22 Wespes E, Schulman CC. Male andropause. Myth, reality and treatment. *Int J Impot Res* 2002; 14: S93–S98
23 Tenover JL. Testosterone and the aging male. *J Androl* 1997; 18: 103–6
24 Zirkin BR, Chen H. Regulation of Leydig cell steroidogenic function during aging. *Biol Reprod* 2000; 63: 977–81
25 Smith TP, Suliman AM, Fahie-Wilson MN, McKenna TJ. Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays. *J Clin Endocrinol Metab* 2002; 87: 5410–5
26 Isidori AM, Caprio M, Strollo F *et al.* Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. *J Clin Endocrinol Metab* 1999; 84: 3673–80
27 Isidori AM, Strollo F, More M *et al.* Leptin and aging. correlation with endocrine changes in male and female healthy adult populations of different body weights. *J Clin Endocrinol Metab* 2000; 85: 1954–62
28 Vermeulen A. Androgen replacement therapy in the aging male – a critical evaluation. *J Clin Endocrinol Metab* 2001; 86: 2380–90
29 Algarte-Genin M, Cussenot O, Costa P. Prevention of prostate cancer by androgens: experimental paradox or clinical reality. *Eur Urol* 2004; 46: 285–94
30 Nieschlag E, Behre HM, Bouchard P *et al.* Testosterone replacement therapy: current trends and future directions. *Hum Reprod Update* 2004; 10: 409–19
31 Wang C, Cunningham G, Dobs A *et al.* Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. *J Clin Endocrinol Metab* 2004; 89: 2085–98
32 Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. *J Clin Endocrinol Metab* 2004; 89: 5462–8
33 Malkin CJ, Pugh PJ, Jones RD, Jones TH, Channer KS. Testosterone as a protective factor against atherosclerosis – immunomodulation and influence upon plaque development and stability. *J Endocrinol* 2003; 178: 373–80
34 Grinspoon S, Corcoran C, Askari H *et al.* Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebocontrolled trial. *Ann Intern Med* 1998; 129: 18–26
35 Grinspoon S, Corcoran C, Stanley T, Baaj A, Basgoz N, Klibanski A. Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. *J Clin Endocrinol Metab* 2000; 85: 60–5
36 Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. *N Engl J Med* 2004; 350: 482–92
37 Morelli A, Filippi S, Mancina R, *et al.* Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. *Endocrinology* 2004; 145: 2253–63
38 Aversa A, Bruzziches R, Spera G. A rationale for the use of testosterone 'salvage' in treatment of men with erectile dysfunction failing phosphodiesterase inhibitors. *The Endocrinologist* 2005; 15: 99–105

Korespondence:
Antonio Aversa,
Dipartimento di Fisiopatologia Medica,
Università di Roma 'La Sapienza'
Viale del Policlinico 155,
00161 Rome, Italy.
e-mail: antonio.aversa@uniroma1.it

Zkratky:
ED, erectile dysfunction; TRT, testosterone-replacement therapy; DHT, dihydrotestosterone; SHBG, sex hormonebinding globulin.